Intergenic lnc-LEP-2:6 and lnc-LEP-2:7 as novel biomarkers associated with type 2 diabetes mellitus.

Context: Type 2 diabetes mellitus (T2DM) has undeniably become a significant threat to public health in the modern world.

Objective: To identify molecules involved in the development of T2DM, the expression patterns of cis-lincRNAs-LEP were investigated in T2DM patients.

Materials And Methods: The expression levels of 11 lncRNAs-LEP and mRNA in 71 diabetic patients and 32 controls were determined using qRT-PCR. The association between lncRNAs-LEP and T2DM was performed using ROC curve analysis.

Results: The expression analysis of lnc-LEP-2:6 and lnc-LEP-2:7 was significantly different (≤ .0001) in diabetic patients compared to the controls. The ROC curve data showed that lnc-LEP-2:6 and lnc-LEP-2:7 have a high AUC, with 0.940 (95% CI: 0.875-0.977) and 0.958 (95% CI: 0.899-0.988), respectively.

Conclusions: Our results revealed two novel biomarkers associated with the T2DM and suggest that the circulating intergenic, lnc-LEP-2:6 and lnc-LEP-2:7, might have a regulatory role in the disease pathogenesis.